reference.medscape.com
Chen L., Shen Y., Luo Q., Yu Y., Lu H., Zhu R. Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary ...
www.mediasphera.ru6 янв 2018 ... We next subjected cells to 10 Gy irradiation, a dose frequently used in clinical ... For the SKOV-3, but not NGP-127 cells, for the TKIs Sorafenib, ...
www.ibch.ruAfter the second cycle of target therapy, the dose of sorafenib was reduced by 50 % due to adverse events; during the next 10 month the patient received ...
www.researchgate.net24 янв 2018 ... "Натива" зарегистрировала в госреестре лекарственных средств препарат " Сорафениб-натив". Этот препарат является дженериком ...
pravo.ruSorafenib in Advanced Hepatocellular Carcinoma Reply ... Patient tolerance can be severely limited, which in turn limits permitted dose and associated patient ...
www.researchgate.netwww.rxlist.com
cancer.emedtv.com
www.drugbank.ca
www.ndrugs.com
www.drugs.com
Применение препарата Нексавар (сорафениб) для лечения ..... A phase II trial of intrapatient 34. dose-escalated sorafenib in patients with metastatic renal ...
cyberleninka.ruSorafenib (co-developed and co-marketed by Bayer and Onyx Pharmaceuticals as Nexavar), is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma)...
en.wikipedia.orgIpratropium bromide, metered dose inhaler 200 doses, 20 mcg/dose. Fenoterol+ Ipratropium bromide ... tablets, 250 mg. Sorafenib, film-coated tablets, 200 mg ...
nativa.proEffectiveness of several multikinase inhibitors (vandetanib, sorafenib, sunitinib) was confirmed in phase. II clinical ..... to sorafenib at a low dose in patients with.
ogsh.abvpress.ruwww.everydayhealth.com
клеточные сигнальные пути (мультикиназные ингибиторы – сорафениб, .... Three-year safety and efficacy of everolimus and low-dose cyclosporine in de ...
pediatriconcology.ruсорафениб (Нексавар), значительно выше таковой в группе ... avoidance of the unneeded dosage reduction that may result in worse therapeutic efficiency.
oncourology.abvpress.ru